Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Delays Ruling on Glaxo Cervical Cancer Vaccine

By Pharmaceutical Processing | September 30, 2009

MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — The FDA has delayed a decision on GlaxoSmithKline’s vaccine for cervical cancer, according to the British drugmaker. The FDA was scheduled to announce its ruling Tuesday on whether to approve Cervarix, but a Glaxo spokeswoman said the review will continue. The announcement came one day after British health officials reported a 14-year-old girl died a few hours after receiving the vaccine. Britain’s National Health Service began offering Cervarix to teenage girls last year, and more than 1.4 million doses of the vaccine have been given out under the program. Glaxo spokeswoman Sarah Alspach said the death did not influence the FDA’s decision to extend its review. “The FDA has not indicated the extended review is related to any safety concern,” Alspach said in a statement. An FDA spokeswoman said the agency does not comment on pending product reviews. Earlier this month, an outside panel of health experts voted that Cervarix appears safe and effective for girls and women ages 10 to 25. The FDA is not required to follow the group’s advice, though it usually does. Cervarix already is approved in nearly 100 other countries, but has been delayed in the U.S. since 2007, when the FDA said it needed additional data. The vaccine blocks the two main viruses that cause most cases of cervical cancer. An approval from FDA would allow London-based Glaxo to compete against Merck’s blockbuster vaccine Gardasil, which has been on the market here since 2006. The human papilloma virus, or HPV, infects about 6 million people in the U.S. each year, and is spread mainly through sexual contact. It usually causes no symptoms and goes away within two years, although rare cases can develop into warts and cancer in both men and women. Last year, nearly 4,000 women died of cervical cancer in the U.S., fewer than 1 percent of all deaths from cancer.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards